#China #Shanghai #Denosumab #Mabwell #MAIWEIJIAN

Mabwell Receives NMPA Approval for MAIWEIJIAN

Mabwell, a leading innovation-driven biopharmaceutical company based in Shanghai, has recently announced significant news regarding its product MAIWEIJIAN, a denosumab injection (RD code 9MW0321). The National Medical Products Administration (NMPA) in China has granted approval for additional indications, allowing the drug to be used for patients dealing with bone metastases from solid tumors and multiple myeloma. This approval is pivotal as it expands the treatment landscape for these challenging conditions.

Expanded Treatment Indications

The newly approved indications aim to assist patients suffering from complications related to bone health. Specifically, MAIWEIJIAN is authorized for conditions that delay or mitigate skeletal-related events such as pathological fractures, spinal cord compression, or the need for bone radiotherapy or surgery. This significant advancement not only demonstrates the efficacy of MAIWEIJIAN but also underscores Mabwell's commitment to enhancing patient care.

Strategic Positioning in the Market

MAIWEIJIAN stands out as one of the first biosimilars approved in China, rivaling established treatments like Xgeva®. The drug had previously received marketing authorization for treating unresectable giant cell tumors in bone in March 2024, which showcased its potential in oncology. Furthermore, in August 2025, it achieved registration approval in Pakistan, marking it as the first biosimilar of Xgeva® approved in that region. Such rapid progress indicates Mabwell's strategic focus on expanding its market presence across various countries, having inked cooperation agreements spanning 33 nations, including Brazil, Thailand, and Egypt.

Clinical Superiority and Efficacy

Mabwell emphasizes that denosumab, the active compound in MAIWEIJIAN, provides considerable advantages over commonly used bisphosphonates. It specifically targets the RANKL (Receptor Activator of Nuclear Factor kappa-B Ligand), effectively blocking the RANKL/RANK/OPG signaling pathway. This targeted mechanism not only combats bone metastases but also showcases superior clinical effectiveness in patients who have not responded to prior bisphosphonate therapy. The safety profile of denosumab is noted to be favorable, particularly because it is not eliminated through renal pathways, reducing the incidence of nephrotoxicity, which is a common adverse effect with traditional treatments.

Clinical research and studies conducted, including publications in peer-reviewed journals like International Immunopharmacology and JAMA Oncology, validate MAIWEIJIAN’s pharmacokinetic and pharmacodynamic similarities to the original drug. These findings establish a robust foundation for the product’s efficacy and safety, broadening the therapeutic options available to clinicians and patients alike.

Looking Ahead

Mabwell's commitment to innovation in biopharmaceuticals is evident as it strives to offer effective therapeutic solutions that cater to global medical needs. The company's mission, “Explore Life, Benefit Health,” encapsulates their forward-thinking approach in oncology and aging-related diseases. As MAIWEIJIAN becomes increasingly integrated into treatment protocols for bone-related conditions stemming from cancer, expectations are high for its impact on patient care and overall health outcomes.

For more detailed information, visit Mabwell's official website. This approval marks a pivotal moment in biopharmaceutical advancements, enhancing treatment options for those affected by severe medical conditions related to bone health.